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Abstract:  West  Nile  virus  (WNV)  is  a  neurotropic,  arthropod-borne  flavivirus  that  is 
maintained in an enzootic cycle between mosquitoes and birds, but can also infect and 
cause disease in horses and humans. WNV is endemic in parts of Africa, Europe, the 
Middle  East,  and  Asia,  and  since  1999  has  spread  to  North  America,  Mexico,  South 
America, and the Caribbean. WNV infects the central nervous system (CNS) and can cause 
severe disease in a small minority of infected humans, mostly immunocompromised or the 
elderly. This review discusses some of the mechanisms by which the immune system can 
limit  dissemination  of  WNV  infection  and  elaborates  on  the  mechanisms  involved  in 
pathogenesis. Reasons for susceptibility to WNV-associated neuroinvasive disease in less 
than 1% of cases remain unexplained, but one favored hypothesis is that the involvement 
of the CNS is associated with a weak immune response allowing robust WNV replication 
in the periphery and spread of the virus to the CNS. 
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1. Introduction 
West  Nile  virus  (WNV)  is  a  neurotropic,  arthropod-borne  flavivirus  with  a  single-stranded  
positive-sense RNA genome. WNV is maintained in an enzootic cycle between mosquitoes and birds, 
but can also infect and cause disease in horses and humans, which serve as incidental dead-end hosts. 
WNV  is  endemic  in  parts  of  Africa,  Europe,  the  Middle  East,  and  Asia  [1],  and  following  its 
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emergence in the United States in 1999 it has rapidly spread across North America, and has recently 
been reported in Mexico, South America, and the Caribbean [2–4]. Currently, no specific therapy or 
vaccine has been approved for use against WNV infection in humans. 
Epidemiological studies indicated that the frequency and severity of clinical illness increases with 
age [5–7]. Infection with WNV remains asymptomatic in the majority of cases or results in West Nile 
fever (a mild flu-like illness) in approximately 20 to 30% of infected cases [7–9]. Symptoms are of 
sudden onset and may include malaise, eye pain, headache, myalgia, gastro-intestinal discomfort and 
rash [8,10–13]. A small percentage of cases may develop encephalitis, meningitis, or acute flaccid 
paralysis (AFP) [6,7,13], and long-term neurological sequelae are common in more than 50% of these 
cases [14–18]. Disease manifestation is explained by neuronal damage in several regions of the brain. 
The fatality rate for hospitalized encephalitic cases is approximately 10%, with increased risk for 
patients with compromised immune systems, advanced age and with underlying conditions such as 
diabetes mellitus [19].  
Despite  the  significance  of  central  nervous  system  (CNS)  pathology  in  severe  disease,  the 
mechanisms by which WNV and other encephalitic flaviviruses cause neuronal injury in vivo have not 
been completely elucidated. The increased risk for immunosuppressed patients seems to suggest that 
an intact immune system is essential for the control of WNV infection. Although peripheral immune 
responses to WNV can prevent encephalitis, up to 40% of immunocompetent animals infected with a 
virulent WNV strain develop lethal neuroinvasive disease [20,21]. In these cases the pathologic effect 
of the immune system cannot be excluded.  
It is interesting to note that several other flaviviruses are known to cause neuroinvasive disease, but 
little is known about the pathogenic mechanisms. There is a need for comparative studies between 
these  different  viruses.  Studies  of  flaviviruses  that  rarely  cause  neuroinvasive  disease  may  also 
contribute  to  a  better  understanding  of  the  mechanisms  involved  in  viral  entry  in  the  brain.  For 
instance,  infection  with  dengue  virus  (DENV),  one  of  the  most  important  arboviral  diseases  of 
humans, may result in severe systemic disease, manifested as hemorrhagic or shock syndrome [22]. 
Although DENV has been considered to be a non-neurotropic virus, recent observations indicate that 
the clinical profile of DENV infection is changing, with neurological manifestations becoming more 
frequent [23,24]. The neuropathogenesis of DENV, and the contribution of viral and host factors to 
neuroinvasive disease are not well understood. Barker et al. [25] noticed that flaviviruses that cause 
hemorrhagic  disease  have  asparagine  (Asn)  at  position  67  of  the  E  protein,  corresponding  to  the 
glycosylation site, whereas neurotropic viruses contain Asp at this position. Experiments should be 
designed to study these associations.  
This review will discuss the immune responses in the periphery and brain necessary for the control 
of WNV infection, as well as the particular responses that may be involved in the development of 
encephalitis. 
2. Tropism 
It is believed that after a mosquito bite WNV infects keratinocytes [26] and Langerhans cells, 
which migrate to regional lymph nodes where initial replication occurs [27–31]. WNV then spreads 
systemically to visceral organs, such as the kidney and spleen, where a second round of replication Viruses 2011, 3 
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takes  place,  presumably  in  epithelium  cells  and  macrophages,  respectively  [32].  Depending  on  
the  level  of  viremia  WNV  can  cross  the  blood-brain  barrier  (BBB)  into  the  brain  and  cause  
meningo-encephalitis. This is similar to what has been observed for other neurotropic viruses, such as 
Saint-Louis  encephalitis  virus  in  mice  [33],  where  the  probability  of  neuroinvasion  appeared  to 
correlate with the level and duration of viremia. The envelope (E) glycoprotein of WNV has been 
implicated in neuroinvasiveness, particularly domain III of the protein, which constitutes the receptor 
binding domain [34–36]. Several mechanisms have been proposed for WNV entry into the CNS:  
(i)  infection  or  passive  transport  through  the  endothelium  or  choroid  plexus  epithelial  cells  [37],  
(ii)  infection  of  olfactory  neurons  and  spread  to  the  olfactory  bulb  [38],  (iii)  a  “Trojan  horse” 
mechanism in which the virus is transported by infected immune cells trafficking to the CNS [39], and 
(iv) direct axonal retrograde transport from infected peripheral neurons [40–42].  
In humans, WNV is most often detected in neurons in the cerebral cortex, thalamus, brainstem, 
basal ganglia, cerebellum, and spinal cord (mainly anterior horn), and in some cases, infection has 
been detected in the olfactory bulb and hippocampus (Figure 1) [43]. WNV has been detected in the 
same regions of the brain of experimentally infected mice as in humans, indicating a similar tropism of 
WNV in humans and mice. The synchronous appearance of virus at many sites in the brain and spinal 
cord  suggests  that  haematogenous  spread  is  an  obvious  way  of  entry  into  the  CNS.  Histological 
analysis of samples from fatal human cases also provided evidence of gliosis, indicating involvement 
of microglial cells and astrocytes during WNV infection. In vitro experiments have shown that WNV 
can infect primary neurons, human and mouse neuroblastoma cells, cortical astrocytes (HBCA), brain 
microvascular endothelial (HBMVE) cells [44,45], and oligodendrocytes [46–49], while infection of 
microglia resulted in low viral yield [44]. So far, animal experiments have only shown infection of 
neurons by WNV [50–53] and have provided limited evidence of in vivo glial cell infection. 
Figure 1. Frequency of infection of several regions of the human brain by West Nile virus. 
The  areas  most  often  infected  by  WNV  include:  the  cerebral  cortex,  thalamus,  basal 
ganglia, brainstem, cerebellum, and spinal cord (anterior horn) (indicated in dark red). 
Infection has less frequently been found in the olfactory bulb and hippocampus (indicated 
in orange). 
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3. Adaptive Immune Response Protects against Severe WNV Infection 
It  has  been  recognized  that  the  elderly  and  immunocompromised  are  especially  at  risk  for 
disseminated WNV infection and for developing fatal encephalitis. Although the exact immunological 
basis for the increased susceptibility in the elderly remains unclear, experiments with mice have begun 
to  elucidate  the  role  of  the  different  components  of  the  innate  and  adaptive  immune  response  in 
controlling infection, in particular the role of immunoglobulin M (IgM), CD4+ and CD8+ T cells. It is 
believed that changes in both innate and adaptive immune function converge in the reduced response 
to vaccination and protection against infection in the elderly [54]. For instance, the decline in thymic 
output of naïve T cells diminishes responses to novel antigens, such as WNV, while clonal expansions 
leading to defects in the T cell repertoire are associated with blunted responses of memory T cells to 
conserved epitopes of the influenza virus [54]. 
Use of a well-characterized mouse model of WNV infection, which in many respects resembles the 
human disease, showed that mice deficient in the production of secreted IgM (sIgM), but still capable 
of expressing surface IgM were vulnerable to lethal infection, even after inoculation with low doses of 
WNV [55]. sIgM−/− mice developed higher levels of infectious virus in sera compared to wild-type 
animals.  This  enhanced  viremia  correlated  with  higher  WNV  burdens  in  the  CNS.  Consistently, 
passive transfer of polyclonal anti-WNV IgM or IgG protected sIgM−/− mice against mortality, while 
administration  of  comparable  amounts  of  a  non-neutralizing  monoclonal  anti-WNV  IgM  did  not 
provide any protection. Overall, these results indicate that the induction of a specific, neutralizing IgM 
response early in the course of WNV infection limits viremia and dissemination of virus into the CNS, 
resulting in protection against lethal infection. Whether the kinetics of the IgM response to WNV 
differs between young and the elderly and how it might affect susceptibility to severe WNV infection 
in humans is not clear. 
Furthermore,  it  has  also been demonstrated that  mice with a genetic or  acquired deficiency in  
CD4+ T lymphocytes display protracted WNV infection in the CNS, leading to uniform lethality by 
50 days after infection [56]. Mice that survived past day 10 had high-level persistent infection in the 
CNS  compared  to  wild-type  mice,  even  up  to  45  days  after  infection.  WNV-specific  IgM  levels 
decreased about 20-fold at day 15 post-infection in CD4-deficient mice and IgG levels were about 
100- to 1,000-fold lower throughout the course of infection compared to wild-type mice. Furthermore,  
WNV-specific CD8+ T-cell activation and trafficking to the CNS were markedly compromised at day 
15. These results suggest that the main protective role of CD4+ T cells during primary infection of 
WNV is to assist in antibody responses and to sustain WNV-specific CD8+ T cell responses in the 
CNS that enable viral clearance.  
CD8+ T cells have been shown to directly play a role in controlling WNV infection and preventing 
severe disease. When mice lacking CD8+ T cells or classical Ia major histocompatibility complex 
(MHC) antigens were infected with a virulent WNV isolate, high viral titers were recovered from the 
CNS and increased mortality rates were recorded [57]. In contrast, absence of CD8+ T cells did not 
affect the quantitative antibody response and did not alter the kinetics or magnitude of viremia during 
primary infection. Interestingly, infectious virus could still be recovered from the CNS of CD8+ T 
cell-deficient mice that survived initial WNV challenge for several weeks. It is interesting however, 
that in spite of the normal quantitative antibody response, WNV was still able to enter the brain, even Viruses 2011, 3 
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though it has been shown that IgM and IgG are important in preventing dissemination of WNV into 
the CNS [55]. These experiments collectively suggest that WNV-specific antibodies are responsible 
for  reducing  viremia  and  preventing  development  of  severe  disease,  while  CD8+  T  cells  play  an 
important  function  in  clearing  infection  from  tissues  and  preventing  viral  persistence.  Whether 
antibodies can prevent neuroinvasion remains to be determined. 
4. Crossing the Blood-Brain-Barrier (BBB) 
Inflammation has been functionally defined as the host response to injury, meant to eliminate the 
cause of damage and promote tissue healing. However, several studies have incriminated inflammation 
in  the  pathogenesis  of  numerous  chronic  diseases  such  as  cancer,  diabetes,  or  neurodegenerative 
conditions. The limited regenerative capacity of neurons makes the CNS particularly susceptible to 
damage mediated by inflammation. For a long time it was assumed that the CNS is protected from 
extensive immunological responses due to restricted leukocyte trafficking from the periphery to the 
CNS, a process erroneously referred to as “immune-privilege”. Initially, CNS immune-privilege was 
attributed to CNS isolation from the immune system by the BBB, the lack of draining lymphatics, and 
the apparent immune-incompetence of microglia, the resident CNS macrophages. However, this view 
has been revisited based on data showing that peripheral immune cells can cross the intact BBB.  
The CNS is populated by three different glial cell populations: (1) astrocytes, (2) microglia, and  
(3) oligodendrocytes. Glial cells are believed to form the immune system in the brain. Astrocytes are  
star-shaped and constitute the most abundant cell type found in the CNS; it has been suggested that 
there  are  approximately  10-times  more  astrocytes  than  neurons  [58,59],  although  a  ratio  of  only  
1.4  [60]  has  also  been  indicated.  Astrocytes  have  a  number  of  important  functions  in  the  brain 
homeostasis, including maintenance of the BBB, regulation of neuronal blood flow, regulation of the 
extracellular potassium balance, providing metabolic support to neurons, and stimulation of myelin 
formation  by  oligodendrocytes.  Although  astrocytes  can  produce  acute-phase  proteins  and  some  
pro-inflammatory  cytokines,  in  general  they  have  limited  innate  immune  properties.  Astrocytes 
contribute to the maintenance of the BBB by creating a network of foot processes called the glia 
limitans. In this regard, astrocytes lie at the gateway to the CNS parenchyma and play a crucial role in 
controlling leukocyte influx.  
Microglia are the resident macrophages of the brain and comprise 10–20% of all glial cells. Their 
main function is to monitor and maintain neuronal health. They are very sensitive and become readily 
activated by most neuropathologic conditions, including inflammatory disease and neuronal injury. 
When activated, microglia display distinct functional plasticity, such as changes in cell morphology, 
cell number, cell surface receptor expression, and production of growth factors and cytokines. It has 
been shown that microglia are immunocompetent, but differ from macrophages and dendritic cells in 
their  ability  to  orchestrate  neuroprotective  lymphocyte  responses.  In  addition,  CNS  neurons  and  
glial  cells  have  been  shown  to  be  capable  of  actively  regulating  macrophage  and  lymphocyte  
responses [61].  
Oligodendrocytes are a type of neuroglia found in the CNS of vertebrates and invertebrates. Their 
function  is  to  produce  myelin,  which  acts  as  an  insulating  sheath  on  the  axons  of  nerve  fibers. 
Oligodendrocytes can be distinguished from astrocytes by their greater density of both the cytoplasm Viruses 2011, 3 
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and  the  nucleus,  the  absence  of  fibrils  and  glycogen  in  the  cytoplasm,  and  the large numbers of 
microtubules in the processes. A single oligodendrocyte can extend its processes to approximately 50 
axons, wrapping around approximately 1 µm of myelin sheath of each axon. 
In mice, WNV crosses the BBB and infects the CNS after the peak viremia (around day 3) [62,63]. 
Several studies showed that immune responses in the brain are necessary to clear the infection. How 
exactly recruitment of leukocytes from blood into the brain parenchyma is regulated is however not 
completely understood. Recent data suggest that leukocytes have to pass two barriers in order to arrive 
in the brain parenchyma: the endothelial cell vascular wall and the glial limitans, collectively referred 
to as BBB (Figure 2). After transmigration of the vascular wall, the majority of infiltrating leukocytes 
are  retained  in  the  perivascular  space,  but  the  factors  that  regulate  this  process  have  not  yet  
been elucidated.  
The chemokine system is a critical aspect of the immune response that controls the migration of 
leukocytes  into  the  brain.  During  infection  chemokines  are  expressed  and  specific  subsets  of 
leukocytes migrate from blood into the brain. The importance of chemokines in controlling WNV 
infection  is  exemplified  by  the  fact  that  chemokine  CXC  motif  receptor  3  (CXCR3)  and  C-C 
chemokine  receptor  type 5 (CCR5)  knock-out  mice cannot  clear  infection and result in increased 
mortality. There is a clear need to define and understand the relative importance of the molecules that 
control  leukocyte  entry  into  the  brain.  For  instance,  it  has  been  shown  that  TNF-α  increases  the 
vascular permeability and allows penetration of leukocytes in the perivascular space.  
Once in the perivascular space, immune cells need to pass the second barrier, the glia limitans. Few 
studies have focused on understanding the molecular and cellular mechanisms regulating leukocyte 
penetration through the glia limitans. Expression of the C-X-C motif chemokine 12 (CXCL12) at the 
perivascular  space  is  probably  responsible  for  retention  of  cells  in  the  perivascular  spaces  of  the  
CNS [64]. In this regard, neutralization of CXCL12 was shown to promote leukocyte entry into the 
brain  parenchyma  [65].  On  the  other  hand,  matrix  metalloproteinases  (MMP),  produced  both  by 
monocytes  and  glia  cells,  have  been  shown  to  be  involved  in  migration  of  leukocytes  to  the 
perivascular space as well as migration through the glia limitans [66].  
A study performed by Verma et al. using HBMVE and HBCA, showed that several MMPs were 
significantly induced in WNV-infected HBCA cells [45]. Incubation of naïve HBMVE cells with the 
supernatant from WNV-infected HBCA cells resulted in loss of tight junctions. These data provided 
evidence that astrocytes represent a source of MMP in the brain, which may lead to disruption of the 
BBB. Degradation of components of the glia limitans is another mechanism facilitating migration of 
leukocytes into the brain parenchyma. Collagen (a component of glia limitans) could be degraded by 
extracellular  proteases  such  as  the  cysteine  protease  cathepsins  K,  S,  and  L  [67,68],  whereas 
conversion  of  plasminogen  into  plasmin  may  lead  to  degradation  of  laminin  or  fibronectin,  
other  important  components  of  the  glia  limitans  [67,69].  When  the  integrity  of  the  BBB  is 
compromised, immune cells may enter the brain, thereby contributing to WNV viral clearance and 
immune mediated damage.  Viruses 2011, 3 
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Figure 2. Regulation of Blood-brain barrier permeability, entry of WNV in the brain and 
factors involved in the pathogenesis of WNV-induced neuroinvasisve disease. Following 
inoculation of WNV in the dermis, virus infects and replicates in cells of the mononuclear 
lineage and neutrophils. Monocytes and neutrophils act as reservoirs for viral replication 
and dissemination, resulting in an increase in viral load. Recognition of WNV replication 
by TLR3 in monocytes leads to production of TNF-α and MMP-9 in a dose-dependent 
manner, resulting in loss of tight junctions, which allows entry of WNV and immune cells 
into the brain. High viral loads facilitate entry and dissemination of WNV into the brain. 
Expression of CXCL12 plays an important role in the retention of immune cells in the 
perivascular  spaces  of  the  CNS.  Production  of  MMPs,  cathepsins  and  plasmin  by 
activated/infected monocytes and glial cells are probably involved in migration of cells 
from the perivascular space into the brain parenchyma. Furthermore, infected glial cells 
and neurons release neurotoxic mediators, leading to neuronal death. Neuronal death is 
mediated for a great part via the caspase-9 and caspase-3 pathway, which is dependent on 
the  capsid  of  WNV.  WNV:  West  Nile  virus;  TNF-α:  Tumor  necrosis  factor-α;  MMP: 
Matrix metalloproteinases; TLR: Toll-like receptor; CXCL: chemokine; IL: Interleukin; 
BBB: Blood-brain barrier; glial limitans: a network of foot processes of astrocytes. 
 Viruses 2011, 3 
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5. Pathogenesis of WNV Neuroinvasive Disease: A Balance between Viral Cytopathology and the 
Immune System 
5.1. Mechanisms of Cell Death 
Programmed  cell  death  can  be  considered  as  a  defense  mechanism  of  the  host  in  response  to 
pathogenic insults. Pathogens may induce cell death to the host either by direct infection of host cells 
(e.g., cytolytic viruses) or by releasing toxic products (e.g., bacterial toxins). Cell death has been 
generally divided in necrosis (accidental, uncontrolled cell death resulting in inflammatory response) 
and  programmed  cell  death,  a  regulated  and  controlled  process,  which  traditionally  has  been 
considered non-inflammatory. Even though programmed cell death is often used as a synonym for 
apoptosis, it is more accurately described as cell death that is dependent on genetically encoded signals 
or activities within the dying cell [70,71]. No cellular activity is required as acute cell breakdown 
occurs as a result of the direct action of a damaging stimulus, and programmed cell death is therefore 
only prevented by the absence of this stimulus [70]. Recent studies have revealed several pathways 
that lead to programmed cell death: apoptosis, pyroptosis, autophagy and oncosis [72]. During viral 
infection,  programmed  cell  death  has  an  antiviral  effect  by  inducing  the  death  of  infected  cells. 
However, cell death can also have pathological effects if it occurs in non-renewing cell populations, 
such as neurons.  
Apoptosis is mediated by a subset of cysteine-dependent aspartate specific proteases, or caspases, 
which can be divided into two functional subgroups: initiator caspases (caspase-2, -8, -9, and -10)  
are mainly involved in activation of the effector caspases-3, -6, and -7, which cleave a variety of 
cellular  substrates.  Apoptosis  involves  nuclear  and  cytoplasmic  condensation  and  formation  of 
membrane-bound cellular fragments or apoptotic bodies.  
Pyroptosis  is  the  proinflammatory  pathway  that  results  from  caspase-1  activity  and  leads  to 
membrane breakdown and proinflammatory cytokine processing. This pathway is uniquely dependent 
on caspase-1 [73–77], which is not involved in apoptosis. Caspase-1 deficient cells are able to respond 
normally to most apoptotic signals [78]. An important function of caspase-1 is to process the proforms 
of the inflammatory cytokines, interleukin (IL)-1β and IL-18, into their active forms [79]. Caspase-1 
activation  or  dependence  has  often  been  observed  during  cell  death  in  the  immune  [80],  central 
nervous [81,82], and cardiovascular systems [83,84]. 
Many studies have shown that WNV induces replication-dependent apoptosis in vitro, and it has 
been hypothesized that virus-induced apoptosis contributes to neuronal death and the pathogenesis of 
encephalic  flaviviruses  [48,85–87].  Experiments  in  mice  have  been  performed  to  analyze  the 
occurrence of apoptosis in vivo. Most studies used the terminal deoxynucleotidyltransferase-mediated 
dUTP-biotin nick end labeling (TUNEL) staining, which detects DNA fragmentation, to confirm that 
apoptosis occurred in the CNS of WNV-infected mice.  
Recently, evidence has been provided that the cell death of WNV-infected neurons is caspase-3 
dependent [88]. It was shown that WNV infection induced caspase-3 activation and apoptosis in the 
brains  of  wild-type  mice,  while  congenic  caspase-3−/−  mice  were  more  resistant  to  lethal  WNV 
infection. It is interesting to note that no significant differences in the tissue viral burdens or the 
kinetics  of  viral  spread  were  found,  but  decreased  neuronal  death  was  observed  in  the  cerebral Viruses 2011, 3 
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cortices, brain stems, and cerebella of caspase-3−/− mice. Consistently, primary neurons derived from 
the  CNS  of  wild-type  mice  showed  caspase-3  activation  and  induction  of  apoptosis  after  WNV 
infection, and treatment with caspase inhibitors resulted in a significant decrease in virus-induced cell 
death. Nonetheless, a deficiency in caspase-3 did not completely protect neurons from WNV-mediated 
death in vitro or in vivo, indicating that caspase-3-independent pathways also contribute to WNV 
pathogenesis. For example, it is possible that the activation of non-caspase proteases, such as calphain 
and cathepsin family proteins is also triggered during WNV infection [89,90].  
Yang et al. showed that direct expression of the WNV capsid protein in the striatum of mouse brain 
or interskeletal muscle caused cell death and inflammation  [87]. Similar effects were observed in 
cultured,  SH-SY5Y  neuroblastoma  cells,  which  could  eventually  be  attributed  to  capsid-induced 
apoptosis  occurring  via  the  mitochondrial  pathway,  involving  caspase-9  and  caspase-3  activation. 
These studies suggest a role for the capsid protein of WNV in viral pathogenesis through the induction 
of the apoptotic cascade. No role for pyroptosis in the pathogenesis of WNV has yet been described. 
However,  WNV  has  been  shown  to  induce  necrosis  in  vitro  in  cells  exposed  to  very  high  viral  
inocula [91]. More effort should be deployed to define the different cell death pathways involved in 
the pathogenesis of severe WNV neuroinvasive disease.  
The function of caspase-12 in viral immunity has not received much attention. Previously, it was 
shown that caspase-12 plays a role in endoplasmic reticulum stress-induced apoptosis in response to 
amyloid toxicity [92]. Wang et al. found that caspase-12-deficient mice had greater mortality, higher 
viral burden in peripheral (serum, lung, spleen) and neural (brain, cerebellum, spinal cord) tissues, and 
defective type I interferon response after WNV challenge compared to wild-type mice [93]. In vitro 
studies of primary neurons and mouse embryonic fibroblasts further demonstrated that caspase-12 
positively  modulated  the  production  of  type  I  interferon  by  regulating  E3  ubiquitin  ligase  
TRIM25-mediated ubiquitination of RIG-1, which is a critical signaling event for the type I interferon 
response  to  WNV  and  other  viral  pathogens.  Alternatively,  high  levels  of  WNV  non-structural  
(e.g., WNV-NS2A, 2B, 4A, 4B) or glycoprotein (WNV-E) may result in endoplasmic reticulum (ER) 
stress and unfolded protein response induction, resulting in apoptosis [94]. 
5.2. Immunopathology  
How much cell injury can be attributed to viral cytopathology and how much to the inflammatory 
response is not known. Infection of neurons with WNV leads to the induction of several cytokines and 
chemokines,  which  promote  leukocyte  invasion  into  the  CNS  and  neuroinflammation  [95,96]. 
However, the extent to which this inflammation contributes to disease pathology remains unclear. In 
particular, the relative contribution of neurons to inflammation is a subject of intensive research.  
Recently, it has been shown that WNV induced the expression of IL-1β, -6, -8, and tumor necrosis 
factor (TNF)-α in human neuroblastoma SK-N-SH cells in a dose- and time-dependent manner, which 
coincided  with  an  increase  in  virus-induced  cell  death  [97].  Treating  cells  with  anti-IL-1β  or  
anti-TNF-α resulted in significant reduction of the neurotoxic effects of WNV. When naïve astrocytes 
were treated with UV-inactivated supernatant from WNV-infected SK-N-SH cells, expression of glial 
fibrillary acidic protein (GFAP) and key inflammatory cytokines were increased. These results suggest 
that neurons are one of the potential sources of pro-inflammatory cytokines in WNV-infected brain, Viruses 2011, 3 
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and that pro-inflammatory mediators are one of the main factors driving WNV-induced neurotoxicity. 
Recent studies with Japanese encephalitis virus (JEV; a closely related neurotropic flavivirus) also 
support a role of TNF-α in cell death, as increased expression of TNF-α receptors in neurons directly 
resulted in the initiation of death cascade via tumor necrosis factor receptor type 1-associated DEATH 
domain protein [98]. 
In animal models of JEV there is some evidence that activation of microglial cells plays a role in 
pathogenesis of encephalitis through the action of pro-inflammatory mediators, which induce neuronal 
cell death [99]. Although reactive gliosis (activation of astrocytes and microglia) has been reported in 
WNV neuroinvasive disease and is considered a key pathogenic feature [100–102], the extent to which 
infection  of  glial  cells  contributes  to  WNV-induced  neurological  disease  has  never  been  fully 
investigated.  It  is  believed  that  collateral  damage  is  mediated  by  inflammatory  factors  that  are  
either  neurotoxic  or  attract  leukocytes  into  the  affected  area,  which  results  in  a  detrimental 
inflammatory milieu.  
Studies performed in Toll-like receptor 3 (TLR3) knock-out mice indicated that reduced production 
of the pro-inflammatory cytokines TNF-α and IL-6 by microglia was associated with their inability to 
promote injury of neuron-like cells and primary mouse neurons, whereas wild-type microglia released 
inflammatory  cytokines  and  induced  neurotoxicity.  Recent  evidence  is  provided  by  observational 
studies  suggesting  that  macrophages  from  young  individuals  can  down  regulate  TLR3  following 
infection with WNV, whereas macrophages of the elderly cannot. Therefore, it has been hypothesized 
that  failure  to  down  regulate  TLR3  in  infected  cells  results  in  production  of  high  levels  of  
pro-inflammatory and vasculogenic cytokines [103].  
Furthermore, a study conducted by van Marle et al. using fatal cases of human WNV encephalitis 
suggested that WNV infects both neurons and glia cells, and that infection of these cells, in particular 
astrocytes,  contributed  to  neuronal  death  by  releasing  neurotoxic  mediators  [95].  This  study  also 
showed an induction of neuroinflammatory genes, where a subset of these genes was specifically 
induced by the capsid protein of WNV. Particularly CXCL10, IL-1β and indolamine-2’,3’-deoxygenase 
(IDO) were shown to be over-expressed in astrocytes ex vivo and in vivo. Interestingly, production of 
CXCL10 by astrocytes has also been implicated in the neuropathogenesis of other viral infections, 
such as human immunodeficiency virus [103–107]. Nonetheless, further studies are needed to define 
the genetic programs associated with neuroprotection or the neurotoxic action of glial cells during 
WNV infection. 
Recently,  a  paradoxical  role  for  neutrophils  in  WNV  pathogenesis  has  been  described.  When  
Bai et al. investigated the role of chemokines in WNV pathogenesis by infecting macrophages from 
mice  with  WNV,  they  found  that  expression  of  CXCL1  and  CXCL2,  which  are  two  CXC-type 
chemokines that induce the migration of neutrophils, was dramatically up-regulated [108]. In addition, 
neutrophils were found to be the most abundant cell type in the peritoneal cavity as early as 12 hours 
after WNV inoculation. These results suggest that neutrophils are the predominant immune cells that 
are initially and rapidly recruited to sites of infection with WNV.  
Interestingly, however, mice depleted of neutrophils had significantly lower WNV in their blood on 
day 2 or 3 after infection, and increased survival rates were seen. In contrast, when mice were infected 
with WNV before the depletion of neutrophils on days 1 and 2 after infection, they showed higher 
levels of viral load as well as reduced survival rates. The authors concluded that WNV may replicate Viruses 2011, 3 
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in neutrophils and increase WNV load in blood early in infection, but that in the later course of 
infection  these  cells  contribute  to  the  control  of  infection.  Eventhough  these  results  should  be 
confirmed, it is tempting to speculate that neutrophils play a critical role in WNV replication and 
dissemination in vivo, especially in humans where neutrophils are the predominant cell type in blood.  
6. Concluding Remarks 
Most studies conducted have elucidated a protective role of the immune system in WNV infection. 
Most  of  our  knowledge  regarding  the  immune  response  and  pathogenesis  has  been  derived  from 
mouse studies. How the responses in birds differ from mammals and how it influences the course of 
disease has not been completely elucidated. Some studies suggest that differences in host response 
between different bird species may influence the outcome of WNV infection [109].  
So far, only few studies have been able to demonstrate a pathogenic role for the immune system in 
inbred mice. A role has been implicated for TNF-α in modulating BBB permeability, and allowing 
dissemination of WNV into the brain where it can infect neurons and possibly glial cells. Direct 
infection of neurons may result in apoptosis via caspase-3 and -9. Furthermore, neurons also respond 
to WNV infection by up-regulating pro-inflammatory cytokines such as IL-1β, -6, -8 and TNF-α, 
which also contribute to neuronal damage. Infection of glial cells leads to up-regulation of CXCL10, 
IL-1β and IDO, and together with expression of MMP by infected astrocytes result in loss of tight 
junction and increased BBB permeability.  
The role of the immune system in pathogenesis of WNV remains speculative. More studies need to 
be done to uncover further evidence for this hypothesis. Reasons why WNV-associated neuroinvasive 
disease is seen in less than 1% of individuals remain unexplained. However, it is plausible that after 
infection, WNV enters the brain of significantly more patients, but that certain host factors, such as an 
overactive inflammatory response, lead to excessive permeability of the BBB, as well as excessive 
neuronal death, eventually overruling the protective effects of the immune system. 
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